Gland Pharma Ltd
Established in Hyderabad, India in 1978, Gland Pharma has grown over the years from a contract manufacturer of small volume liquid parenteral products, to become one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India and other markets. We operate primarily under a business to business (B2B) model and have an excellent track record in the development, manufacturing and marketing of complex injectables. This presence across the value chain has helped us witness exponential growth. We are promoted by Shanghai Fosun Pharma, a global pharmaceutical major.
- Market Cap ₹ 30,393 Cr.
- Current Price ₹ 1,845
- High / Low ₹ 2,196 / 861
- Stock P/E 43.8
- Book Value ₹ 504
- Dividend Yield 0.00 %
- ROCE 14.8 %
- ROE 10.9 %
- Face Value ₹ 1.00
Pros
- Company is almost debt free.
- Company is expected to give good quarter
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|
2,633 | 3,463 | 4,401 | 3,625 | 4,912 | |
1,678 | 2,161 | 2,890 | 2,600 | 3,769 | |
Operating Profit | 955 | 1,302 | 1,510 | 1,025 | 1,143 |
OPM % | 36% | 38% | 34% | 28% | 23% |
139 | 135 | 224 | 184 | 111 | |
Interest | 7 | 3 | 5 | 7 | 18 |
Depreciation | 95 | 99 | 110 | 147 | 290 |
Profit before tax | 993 | 1,335 | 1,619 | 1,055 | 945 |
Tax % | 22% | 25% | 25% | 26% | |
773 | 997 | 1,212 | 781 | 659 | |
EPS in Rs | 49.88 | 60.94 | 73.75 | 47.42 | 40.00 |
Dividend Payout % | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 11% |
TTM: | 25% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 3% |
TTM: | -30% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | -10% |
1 Year: | 47% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 16% |
Last Year: | 11% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|
Equity Capital | 16 | 16 | 16 | 16 | 16 |
Reserves | 3,631 | 5,887 | 7,141 | 7,942 | 8,290 |
5 | 5 | 5 | 4 | 357 | |
435 | 588 | 671 | 814 | 1,629 | |
Total Liabilities | 4,086 | 6,496 | 7,834 | 8,778 | 10,293 |
968 | 954 | 1,502 | 1,571 | 3,703 | |
CWIP | 188 | 338 | 191 | 177 | 320 |
Investments | 0 | 0 | 155 | 0 | 0 |
2,929 | 5,204 | 5,986 | 7,030 | 6,270 | |
Total Assets | 4,086 | 6,496 | 7,834 | 8,778 | 10,293 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|
701 | 605 | 791 | 364 | |
-761 | -1,520 | -999 | 1,211 | |
-7 | 1,238 | 35 | 15 | |
Net Cash Flow | -67 | 323 | -174 | 1,590 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|
Debtor Days | 83 | 71 | 89 | 88 |
Inventory Days | 250 | 312 | 205 | 421 |
Days Payable | 82 | 97 | 80 | 127 |
Cash Conversion Cycle | 251 | 286 | 214 | 382 |
Working Capital Days | 161 | 169 | 168 | 242 |
ROCE % | 28% | 25% | 15% |
Documents
Announcements
- Closure of Trading Window 2d
- Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 25 Mar
-
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
25 Mar - Allotment of 2,400 Equity Shares on exercise of ESOP
-
Announcement under Regulation 30 (LODR)-Change in Management
25 Mar - Changes among Senior Management Personnel of the Company
- Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 19 Mar
Annual reports
Concalls
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT
-
Aug 2023Transcript PPT REC
-
May 2023Transcript PPT
-
Jan 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Oct 2022TranscriptNotesPPT
-
Jul 2022Transcript PPT
-
May 2022Transcript PPT
-
Jan 2022Transcript PPT
-
Nov 2021Transcript PPT
-
Sep 2021TranscriptNotesPPT
-
Jul 2021Transcript PPT
-
May 2021Transcript PPT
-
Feb 2021TranscriptPPT
-
Dec 2020TranscriptPPT
Revenue breakup
Gland Pharma is primarily a contract manufacturer of injectables, with B2B segment generating ~95% of revenues in FY22 [1]